Home Biosimilar Antibodies Others ADC Sacituzumab govitecan
For research use only. Not for use in humans.

Sacituzumab govitecan

Synonyms: IMMU-132

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa. This product is supplied as 10mg/ml PBS solution.

Sacituzumab govitecan

CAS No. 1491917-83-9 (Sacituzumab govitecan)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 98.93% Protein concentration: 10mg/ml Endotoxin Level: ＜1EU/mg
98.93

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa. This product is supplied as 10mg/ml PBS solution.

Product Details

CAS No. 1491917-83-9 (Sacituzumab govitecan)
Molecular Weight 160000
DAR 7.6
ADC antiody Sacituzumab
ADC cytotoxin SN-38
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07178730 NOT_YET_RECRUITING Drug: Sacituzumab govitecan|Drug: Pembrolizumab 25 mg/1 ML I Breast Cancer; Triple-negative Breast Cancer Women's Cancer Study Group GmbH 2026-08-30 PHASE3
NCT06431633 RECRUITING Drug: Zimberelimab|Drug: Sacituzumab govitecan|Drug: Cisplat Lung Diseases; Carcinoma, Non-Small-Cell Lung; Resectable Lung Non-Small Cell Carcinoma Fundación GECP 2025-02-04 PHASE3
NCT06040970 RECRUITING Drug: Sacituzumab|Drug: Cisplatin Ovarian Cancer; Malignant Neoplasm of Uterus Icahn School of Medicine at Mount Sinai 2024-10-28 PHASE1; PHASE2
NCT06524544 RECRUITING Drug: Carboplatin|Drug: Cisplatin|Drug: Docetaxel|Drug: Gemc Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma National Cancer Institute (NCI) 2025-12-02 PHASE3
NCT07271992 NOT_YET_RECRUITING Drug: SG+I TNBC, Triple Negative Breast Cancer First Hospital of China Medical University 2025-12-15 PHASE2
NCT06963905 RECRUITING Drug: Relatlimab FDC + Nivolumab|Drug: Sacituzumab Govitecan Metastatic Triple-negative Breast Cancer Yale University 2025-12-29 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-05)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.